Biotricity logo

BiotricityNASDAQ: BTCY

Profile

Sector:

Healthcare

Country:

United States

IPO:

16 February 2018

Next earnings report:

21 February 2025

Last dividends:

N/A

Next dividends:

N/A
$7.73 M
-79%vs. 3y high
15%vs. sector
-vs. 3y high
-vs. sector
-101%vs. 3y high
13%vs. sector
-90%vs. 3y high
16%vs. sector

Price

regular market | Wed, 20 Nov 2024 14:30:00 GMT
$0.31-$0.06(-14.89%)

Dividend

No data over the past 3 years
$3.27 M-$1.56 M

Analysts recommendations

Institutional Ownership

BTCY Latest News

Biotricity, Inc. (BTCY) Q2 2025 Earnings Call Transcript
seekingalpha.com15 November 2024 Sentiment: NEUTRAL

Biotricity, Inc. (OTC:BTCY) Q2 2025 Earnings Conference Call November 15, 2024 4:30 PM ET Company Participants Dr. Waqaas Al-Siddiq - Founder and CEO John Ayanoglou - Chief Financial Officer Conference Call Participants Kevin Dede - H.C. Wainwright Operator Greetings.

Biotricity Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025
globenewswire.com15 November 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Biotricity Inc.  (OTCQB: BTCY) (“Biotricity” or the “Company”), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the second quarter of fiscal 2025 year and (unaudited) ended September 30, 2024.

Biotricity to Host Second Quarter Fiscal Year 2025 Financial Results and Business Update Call on November 15th
globenewswire.com13 November 2024 Sentiment: POSITIVE

Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Biotricity Inc.  (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fourth Quarter Fiscal Year 2024 Financial Results and Business Update Call on November 15, 2024.

Delisting of Securities of Gamer Pakistan Inc.; Biotricity, Inc.; Zalatoris II Acquisition Corp.; Warrantee Inc.; Spectaire Holdings, Inc.; Centogene N.V.; DZS Inc.; Corner Growth Acquisition Corp. 2; Collective Audience, Inc.; Grom Social Enterprises Inc.; Fintech Ecosystem Development Corp.; Edgio, Inc.; Kineta, Inc.; BurgerFi International Inc.; A SPAC II Acquisition Corp.; and African Agriculture Holdings Inc. from The Nasdaq Stock Market
globenewswire.com10 October 2024 Sentiment: NEGATIVE

NEW YORK, Oct. 10, 2024 (GLOBE NEWSWIRE) --  The Nasdaq Stock Market announced today that it will delist the common stock of Gamer Pakistan Inc. Gamer Pakistan Inc.'s securities were suspended on August 5, 2024, and have not traded on Nasdaq since that time.

Biotricity Announces Inclusion as a Supplier to A Prominent Medical System That Services 21 States
accesswire.com26 September 2024 Sentiment: POSITIVE

REDWOOD CITY, CA / ACCESSWIRE / September 26, 2024 / Biotricity Inc. (OTCQB:BTCY), a leading Technology-as-a-Service (TaaS) company that is redefining the healthcare industry with cutting-edge remote monitoring and diagnostic solutions, announces its inclusion as a supplier to another major medical system that encompasses 60,000 care providers over 400 hospitals and 400 care centers. In the U.S. today, 121.5 million adults have some form of cardiovascular disease.

Biotricity Kicks off Another Pilot Program with a Major Hospital System that Services over 800K Individuals
accesswire.com19 September 2024 Sentiment: POSITIVE

REDWOOD CITY, CA / ACCESSWIRE / September 19, 2024 / Biotricity Inc. (OTCQB:BTCY), a leading Technology-as-a-Service (TaaS) company that is redefining the healthcare industry with cutting edge remote monitoring and diagnostic solutions, announces the launch of a new cardiac monitoring pilot program with a top hospital system. With 90% of U.S. adults at risk of developing cardiovascular disease and a projected shortage of up to 124K physicians in the next 12 years, the demand for Biotricity's innovative cardiac monitoring solutions has never been more urgent.

Biotricity Reports Continued Margin Improvement and Reduced Losses in its First Quarter Fiscal Year 2025
accesswire.com21 August 2024 Sentiment: POSITIVE

The Company shows continued progress towards cash-flow break even and profitability Recurring Technology Fee (SaaS) revenue - over 94% of total revenue with a 76% gross margin, which rose over 400 basis points and is expected to continue to trend higher Gross margins improved significantly to 73.8 from 63.5% in the same period last year, and 59.6% 2 years earlier Reduced SG&A to $3 million, down 16% compared to same period last year Operating loss of $1.1 million, indicated efficiency gains of $1.2 million from the preceding year quarter - a 51.8% improvement Growth in revenue of 6% YOY to $3.2 million EBITDA and Adjusted EBITDA improved by 18.9% and 49.8%, respectively, from the corresponding period in the prior year; Quarter over preceding Quarter, EBITDA improved by $1M, or 36%, whereas Adjusted EBITDA improved by $1.5M or 59%. Comprehensive loss was reported at $6.9 million, due to one-time non-cash items of $3.2 million; removing these would have resulted in a net loss of $3.7 million, consistent with prior year levels of $3.8 million due to interest rate increases that countered the impact of efficiency gains REDWOOD CITY, CA / ACCESSWIRE / August 21, 2024 / Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the first quarter of fiscal 2025 year ended June 30, 2024.

Biotricity Announces Continued Margin Improvement Driven by its Proprietary AI Cloud
accesswire.com22 July 2024 Sentiment: POSITIVE

REDWOOD CITY, CA / ACCESSWIRE / July 22, 2024 / Biotricity Inc. (Nasdaq:BTCY), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced ongoing improvements in operational efficiency, scalability and margin performance driven by the latest enhancements to the company's proprietary AI Cloud platform. The latest version of Biotricity's AI Cloud has improved the company's tech stack efficiency by 20%, which is expected to result in a topline margin improvement of 200 to 300 basis points (2 to 3%) in the coming quarters.

Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
accesswire.com19 July 2024 Sentiment: POSITIVE

ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 20, at 7 p.m.

Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
accesswire.com12 July 2024 Sentiment: POSITIVE

ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (Nasdaq:BTCY) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 13, at 7 p.m. Eastern Time (ET).

  • 1(current)

What type of business is Biotricity?

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. Biotricity, Inc. is based in Redwood City, California.

What sector is Biotricity in?

Biotricity is in the Healthcare sector

What industry is Biotricity in?

Biotricity is in the Medical Devices industry

What country is Biotricity from?

Biotricity is headquartered in United States

When did Biotricity go public?

Biotricity initial public offering (IPO) was on 16 February 2018

What is Biotricity website?

https://www.biotricity.com

Is Biotricity in the S&P 500?

No, Biotricity is not included in the S&P 500 index

Is Biotricity in the NASDAQ 100?

No, Biotricity is not included in the NASDAQ 100 index

Is Biotricity in the Dow Jones?

No, Biotricity is not included in the Dow Jones index

When was Biotricity the previous earnings report?

No data

When does Biotricity earnings report?

The next expected earnings date for Biotricity is 21 February 2025